| ［1］ Badiani B, Maratea D, Messori A. Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis［J］. World J Clin Oncol, 2015, 6(4): 73-79. DOI: 10.5306/wjco.v6.i4.73.
［2］龚志敏, 徐细明, 朱言亮. 雷替曲塞联合紫杉醇二线治疗晚期胃癌的临床研究［J］. 实用临床医药杂志, 2015, 19(19): 19-21, 25. DOI: 10.7619/jcmp.201519006.
［3］谢海彬, 冯锦, 尹勇, 等. 雷替曲塞治疗晚期胃癌临床疗效的Meta分析［J］. 国际肿瘤学杂志, 2015, 42(7): 512-515. DOI: 10.3760/cma.j.issn.1673-422X.2015.07.009.
［4］Wilson KS, Malfair Taylor SC. Raltitrexed: optimism and reality［J］. Expert Opin Drug Metab Toxicol, 2009, 5(11): 1447-1454. DOI: 10.1517/17425250903307455.
［5］Liu Y, Wu W, Hong W, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer［J］. Clin Res Hepatol Gastroenterol, 2014, 38(2): 219-225. DOI: 10.1016/j.clinre.2013.11.006.
［6］Huang D, Ba Y, Xiong J, et al. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer［J］. Eur J Cancer, 2013, 49(14): 2995-3002. DOI: 10.1016/j.ejca.2013.05.021.
［7］Kwon HJ, Park MI, Park SJ, et al. Efficacy and safety of FOLFIRI after failure of FOLFOX-4 in advanced gastric cancer［J］. Korean J Gastroenterol, 2015, 66(1): 10-16. DOI: 10.4166/kjg.2015.66.1.10.
［8］Bozkurt O, Karaca H, Ciltas A, et al. Efficacy and safety of raltitrexed combinations with uraciltegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO)［J］. Asian Pac J Cancer Prev, 2014, 15(4): 1845-1849.
［9］阎昭, 薛津怀, 朱仲玲. 注射用雷替曲塞在结、直肠肿瘤患者体内的药动学［J］. 中国医院药学杂志, 2010, 30(9): 749-752. |
